InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
1
T+90 hit rate
67%
T+90 mean return
+0.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by MARK MILLER, Directeur Exécutif Affaires Médicales. Officer active across 1 company, notably BIOMERIEUX. Aggregated, 4 disclosures have been logged. Split: 2 buys · 1 sell. Total volume traded: €182k. Activity tracked since 26 February 2022. The latest transaction was filed on 4 September 2023 (Cession). Regulator: AMF. The full history is accessible without signup.
Declarations4 total
1,567 shares@ €96.03281.2% of flowActionEuronext Paris2023DD926508
3,625 shares0ActionHors plateforme de négociation2023DD926507
300 shares@ US$115.8218.8% of flowActionHors plateforme de négociation2023DD916808
Ideal exit: 19 Mar 2024 (T+270)
6,052 shares0ActionAcquisition d'actions gratuite2022DD824952
Ideal exit: 23 Nov 2022 (T+270)
4 of 4 declarations
About MARK MILLER
Mark Miller is the Executive Vice President, Chief Medical Officer at BIOMERIEUX. He oversees the medical and strategic operations of the company, playing a key role in developing diagnostic solutions. His expertise in the healthcare sector is essential for innovation and growth.
